Letter to the Editor on the “Code of practice to prevent and reduce pyrrolizidine alkaloid contaminations of medicinal products of plant origin”

Journal of Applied Research on Medicinal and Aromatic Plants

Volumn 4, Issue , 2017, Pages 82-

  Steinhoff, Barbara ^a  

^a BUNDESVERBAND DER ARZNEIMITTEL HERSTELLER E V BAH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT MEDICINAL PRODUCT; PYRROLIZIDINE ALKALOID;

DRUG CONTAMINATION; DRUG MANUFACTURE; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 85012913891     PISSN: None     EISSN: 22147861     Source Type: Journal    
DOI: 10.1016/j.jarmap.2017.01.003     Document Type: Letter

References (3)

1. BfArM, German Federal Institute for Drugs and Medical Devices. Announcement on the test of the content of pyrrolizidine alkaloids to ensure the quality and safety of medicinal products that contain herbal substances or herbal preparations or homeopathic preparations made of herbal starting materials as active substances. 2016 Available at http://www.bfarm.de/SharedDocs/Bekanntmachungen/DE/Arzneimittel/besTherap/bm-besTherap-20160301-pa-pdf.html. (Accessed 23 January 2017).
2. HMPC, Public Statement on the Use of Herbal Medicinal Products Containing Toxic, Unsaturated Pyrrolizidine Alkaloids (PAs). Final. 2014 Available at http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2014/12/WC500179559.pdf. (Accessed 23 January 2017).
3. HMPC, Public Statement on contamination of herbal medicinal products/traditional herbal medicinal products with Pyrrolizidine Alkaloids. 2016 Alkaloids. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2016/06/WC500208195.pdf. (Accessed 23 January 2017).